ALEXION REACHES AGREEMENT WITH FDA FOR PHASE III
ECULIZUMAB.
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), Cheshire, Conn., has
received written confirmation from the U.S. Food and Drug Administration
(FDA) indicating agreement with the two protocols . . .
AGENSYS/GENENTECH SIGN COLLABORATION/LICENSE AGREEMENT.
Agensys, Inc., Santa Monica, Calif., a cancer biotechnology
company, has signed an agreement with Genentech Inc. (NYSE: DNA) for the
research, development and commercialization of therapeutic . . .
HYBRIDON'S OLIGONUCLEOTIDES SHOW POTENT ADJUVANT
ACTIVITY.
Hybridon, Inc. (AMEX: HBY), Cambridge, Mass., has presented
preclinical results illustrating that its 2nd generation
immunomodulatory oligonucleotide (IMO) compounds demonstrated potent
adjuvant . . .
SOMALOGIC GETS RIGHTS TO DNA MODIFICATION PATENTS.
SomaLogic, Inc., Boulder, Colo., a privately held proteomics
company, has significantly expanded its intellectual property base by
acquiring an exclusive license to several key foreign and . . .
DYAX/GENZYME PHASE II TRIAL OF DX-88 MEETS ENDPOINT.
Dyax Corp. (Nasdaq:DYAX) and Genzyme Corporation (Nasdaq:GENZ) have
announced positive initial results from their Phase II, double-blind
placebo-controlled clinical trial of DX-88 for the treatment . . .
BIOSANTE COMPLETES PHASE II TRIAL FOR FSD.
BioSante Pharmaceuticals, Inc. (Amex: BPA), Lincolnshire, Ill. has
completed its Phase II clinical trial of LibiGel(TM) (transdermal
testosterone gel) for the treatment of female sexual dysfunction . . .
EXELIXIS STARTS PHASE 3 TRIAL OF XL119 FOR BILE DUCT
CANCER.
Exelixis, Inc. (Nasdaq: EXEL) South San Francisco, Calif., has
initiated the Phase 3 clinical trial of XL119 (becatecarin) as a
potential treatment for patients with bile duct cancer. The Phase . . .
GLOUCESTER PHASE 2 CLINICAL TRIAL WITH FK228 ENCOURAGING.
Gloucester Pharmaceuticals, Inc., Cambridge, Mass. a privately held
cancer therapeutics development company, has announced that encouraging
interim results from an ongoing NCI-sponsored Phase 2 . . .
BAYLOR LICENSES NOROVIRUS VACCINE TECHNOLOGIES TO
LICOCYTE.
LigoCyte Pharmaceuticals, Inc., Bozeman, Mont. has executed an
exclusive option from Baylor College of Medicine for a license to
technologies related to norovirus vaccines and therapeutics.
"We . . .
453 LIFE SCIENCES AWARDED $2.4 MILLION NHGRI GRANT.
454 Life Sciences, Branford, Conn. a majority-owned subsidiary of
CuraGen Corporation (Nasdaq: CRGN), has received a two-year, $2.4
million grant from the National Human Genome Research Institute . . .
ORPHAN MEDICAL GETS POSITIVE XYREM CLINICAL RESULTS.
Orphan Medical, Inc. (Nasdaq:ORPH), Minneapolis, has received
strong positive data across both primary and secondary endpoints from
its Phase III(b) clinical trial known as SXB-15. The trial . . .
NEWNEURAL GETS SBIR GRANT FOR NN-818 STEM CELL TREATMENT.
NewNeural LLC, Lisle, Ill., a biotechnology company developing
products to help the brain replace cells damaged or destroyed by disease
or injury, has been awarded a Phase I Small Business . . .
INSPIRE LAUNCHES CLINICAL TRIAL FOR RETINAL DETACHMENT.
Inspire Pharmaceuticals, Inc. (Nasdaq: ISPH), Durham, N.C. has
launched a Phase II clinical trial for INS37217 Ophthalmic (denufosol
tetrasodium) for the treatment of rhegmatogenous retinal . . .
MEDIMMUNE/CERUS CO-DEVELOPING THERAPEUTIC CANCER VACCINE.
MedImmune, Inc. (Nasdaq: MEDI) and Cerus Corporation (Nasdaq: CERS)
have signed an agreement for developing and commercializing a novel
therapeutic vaccine designed to treat cancers of the breast, . . .
DOWPHARMA/BRISTOL-MYERS SUIBB SIGN SOLIBILIZATION PACT.
Dowpharma, Midland, MI, a business unit of The Dow Chemical
Company, has signed an agreement to apply advanced particle engineering
technologies designed to deliver solubilization benefits to . . .
DUKE/ARDAIS LAUNCH BIOREPOSITORY FOR CANCER RESEARCH.
Ardais Corporation and Duke University Medical Center have
announced the establishment of a new Biorepository that will provide
human biomaterials and clinical data for clinical research in cancer . . .
BIOE/USC TO DEVELOP NON-EMBRYONIC STEM CELL THERAPIES.
BioE, Inc., St. Paul, Minn., a biotechnology company that develops
antibody-based diagnostics and therapeutics, has entered into a
collaborative research agreement with the University of . . .
HYBRIDON REPORTS BENEFITS OF IMO FOR ALERGIC ASTHMA.
Hybridon, Inc. (AMEX: HBY), Cambridge, Mass., has given two
presentations of preclinical data that suggest its novel
second-generation immunomodulatory oligonucleotide (IMO) compounds have
potent . . .
NEXMED REPORTS POSITIVE RESULTS FOR EARLY EJACULATION
PRODUCT.
NexMed, Inc. (Nasdaq: NEXM), Robbinsville, NJ, a developer of
innovative treatments based on the NexACT(r) drug delivery technology,
has reported positive results from an international pilot study . . .
ENZO BIOCHEM REPORTS INTERIM RESULTS FOR ALEQUEL TRIAL.
Enzo Biochem, Inc. (ENZ), Farmingdale, N.Y., a biotechnology
company specializing in gene identification and genetic and immune
regulation technologies for diagnostic and therapeutic applications, . . .
|
|